FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileMorphoSys AG
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
MOR
MorphoSys AG Stock AnalysisComprehensive stock analysis for MorphoSys AG (MOR) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisMOR
MOR
MorphoSys AG
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
MOR
  1. Home
  2. Stocks
  3. MorphoSys AG

MorphoSys AG

🇺🇸MOR•NASDAQ

MorphoSys AG

🇺🇸MOR•NASDAQ
Market cap
$11.41B

Your view on MOR

Mkt Cap
$11.41B
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About MorphoSys AG

Industry
Biotechnology
Sector
Healthcare
CEO
Arkadius Pichota
Headquarters
DE
Industry
Biotechnology
Sector
Healthcare
CEO
Arkadius Pichota
Headquarters
DE
Description

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States.

It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.

The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2.

In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases.

MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma.

The company was founded in 1992 and is headquartered in Planegg, Germany.

FRC Research

Past Reports

Historical coverage archive.

*MorphoSys AG had paid FRC a fee for research coverage and distribution of reports. This fee creates a potential conflict of interest which readers should consider.

3 reports
Jan 19, 2012

Positive PEA on Tami Mosi Magnesium Project

PDF
Aug 30, 2009

NI 43-101 Magnesium Resource for Tami-Mosi Project, Nevada

PDF
Jan 15, 2008

Initiating Coverage; Two fold commodity approach in North America

PDF
Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for MorphoSys AG. Starting points for MorphoSys AG: EPS -$1.38, beta 0.66 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for MorphoSys AG. Trailing twelve-month EPS for MorphoSys AG stands at -$1.38. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 20, 2026 · EUR

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Analyst Ratings

Buy10 ratings
  • Strong Buy0
  • Buy5
  • Hold5
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrJun 2024Next QtrSep 2024Current YearFY Dec 2024Next YearFY Dec 2025
Avg. estimateEUR 0.00−EUR 0.56−EUR 2.38−EUR 1.37
Low estimateEUR 0.00−EUR 0.56−EUR 2.69−EUR 2.14
High estimateEUR 0.00−EUR 0.56−EUR 1.88−EUR 0.58
No. of analysts0143
Year-ago EPS−EUR 0.541−EUR 0.871−EUR 1.381—
Growth————

1Year-ago EPS includes one-time items; growth not shown.

Revenue Estimate

RevenueCurrent QtrJun 2024Next QtrSep 2024Current YearFY Dec 2024Next YearFY Dec 2025
Avg. estimateEUR 29.05MEUR 50.29MEUR 220.26MEUR 324.17M
Low estimateEUR 29.05MEUR 50.29MEUR 173.12MEUR 317.28M
High estimateEUR 29.05MEUR 50.29MEUR 267.41MEUR 331.05M
No. of analysts1123
Year-ago revenueEUR 53.17MEUR 63.80MEUR 238.28M—
Growth−45.4%−21.2%−7.6%—
Recent analyst actions15 rating and price-target changes, latest Mar 14, 2024 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 20, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for MorphoSys AG. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold MOR12 companies
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
JBIOJade Biosciences, Inc.HealthcareNASDAQ$1.1B
JSPRJasper Therapeutics, Inc.HealthcareNASDAQ$12.8M
JSPRWJasper Therapeutics, Inc.HealthcareNASDAQ$3,251
JUNSJupiter Neurosciences, Inc.HealthcareNASDAQ$2.0M
JWCTFJW (Cayman) Therapeutics Co. LtdHealthcareOTC$127.5M
KALAKALA BIO, Inc.HealthcareNASDAQ$2.1M
KAPAKairos Pharma, Ltd.HealthcareAMEX$1.5M
KARDKardigan, Inc.HealthcareNASDAQ$1.1B
KLDOKaleido Biosciences, Inc.HealthcareOTC$4,262
KLRAKailera Therapeutics, Inc.HealthcareNASDAQ$1.5B
KLRSKalaris Therapeutics IncHealthcareNASDAQ$32.6M
KNBIFKane Biotech Inc.HealthcareOTC$4.6M
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for MorphoSys AG. Coverage tracks MorphoSys AG within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of MorphoSys AG.

News

Latest Market News